靶向微小RNA-22可抑制三阴性乳腺癌小鼠模型中的肿瘤扩散。

Targeting of microRNA-22 Suppresses Tumor Spread in a Mouse Model of Triple-Negative Breast Cancer.

作者信息

Panella Riccardo, Cotton Cody A, Maymi Valerie A, Best Sachem, Berry Kelsey E, Lee Samuel, Batalini Felipe, Vlachos Ioannis S, Clohessy John G, Kauppinen Sakari, Pandolfi Pier Paolo

机构信息

Cancer Research Institute, Beth Israel Deaconess Cancer Center, Departments of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.

Center for Genomic Medicine, Desert Research Institute, Reno, NV 89512, USA.

出版信息

Biomedicines. 2023 May 18;11(5):1470. doi: 10.3390/biomedicines11051470.

microRNA-22 (miR-22) is an oncogenic miRNA whose up-regulation promotes epithelial-mesenchymal transition (EMT), tumor invasion, and metastasis in hormone-responsive breast cancer. Here we show that miR-22 plays a key role in triple negative breast cancer (TNBC) by promoting EMT and aggressiveness in 2D and 3D cell models and a mouse xenograft model of human TNBC, respectively. Furthermore, we report that miR-22 inhibition using an LNA-modified antimiR-22 compound is effective in reducing EMT both in vitro and in vivo. Importantly, pharmacologic inhibition of miR-22 suppressed metastatic spread and markedly prolonged survival in mouse xenograft models of metastatic TNBC highlighting the potential of miR-22 silencing as a new therapeutic strategy for the treatment of TNBC.